Equity Overview
Price & Market Data
Price: $1.15
Daily Change: -$0.22 / 19.13%
Range: $1.12 - $1.16
Market Cap: $14,097,711
Volume: 116,544
Performance Metrics
1 Week: 77.97%
1 Month: 95.99%
3 Months: -13.29%
6 Months: -62.36%
1 Year: -91.44%
YTD: -65.75%
Company Details
Employees: 23
Sector: Health technology
Industry: Medical specialties
Country: United States
Details
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.